Oncotelic Announces Peer-Reviewed Validation of Deciparticle™ Platform Supporting Clinical Development of Sapu003
Oncotelic and Sapu Nano announced a peer-reviewed publication in the International Journal of Molecular Sciences validating the Deciparticle platform and the Sapu003 intravenous everolimus formulation. The paper details a scalable cGMP manufacturing process and favorable stability profile for Sapu003, which is currently in a Phase 1b trial for advanced mTOR-sensitive solid tumors.
Key figures
- Drug Name
- Sapu003
- Phase Of Trial
- Phase 1b
- Particle size
- below 20 nanometers
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.